June 23rd, 2015|

Symetrica, the Technology Venture Partners portfolio company providing radiation detection solutions company has announced the appointment of David Price as Non-executive Chairman.

David Price was formerly CEO of Chemring Group plc, the FTSE 250 listed with revenues of £600m. Chemring is a specialist manufacturer of expendable countermeasures, advanced electronics and energetic materials for the global defence, security and safety markets. Prior to Chemring, David was MD of Rolls Royce Naval Marine, a division supplying propulsion systems, products & services to 59 navies for both submarine and surface ship applications. Naval Marine is a global business with a turnover of over £450m per year and employing 2900 staff. It undertook the design authority role for all Royal Navy nuclear reactor systems and manufactured all of the key components for the Pressurised Water Reactor.

About Symetrica

Symetrica is a leading supplier of advanced isotope detection and identification technologies for the Homeland Security market. Symetrica was originally a spinout company from the Department of Physics and Astronomy at the University of Southampton. The core technology has been developed into a suite of products that detect and accurately identify threat materials, even when masked by innocent radioactive material or in the presence significant shielding. This greatly increases efficiency at detection points such as ports and borders by distinguishing threat material from legitimate radiological materials. The products include both handheld and vehicle portals detection systems. Symetrica solutions are in use at a range of customers across the world including the US Department for Homeland Security. www.symetrica.com

About Technology Venture Partners

Technology Venture Partners is venture capital firm investing in early stage technology companies in the South of the UK. TVP invests in high growth companies across a broad range of technology sectors including enterprise and infrastructure software, communications and networking, electronics, advanced materials, medical technology and healthcare IT. TVP portfolio companies include Atlas Genetics (point of care DNA based diagnostics for infectious diseases), Symetrica (radiation detection for security applications), Micrima (radiowave based imaging for breast cancer detection) and Dynmark (cloud based mobile messaging and analytics). Several of the South West Venture Fund portfolio companies were originally spinouts from leading universities and research institutions located in the South of the UK. www.techvp.co.uk